SCM Pharma Expands

SCM Pharma has expanded its potent capacity following an $810,000 investment at its UK-based facility. The expansion includes an additional dedicated suite to handle and fill highly potent products such as cytotoxics to cGMP, as well as a new 500-sq.-ft cleanroom dedicated to making potent products. Additionally, the company has developed a production technique to handle continuous throughput via isolators to boost its aseptic processing capacity.

Along with potent products, the company also provides sterile fill finish of C14 radio-labelled compounds to GMP standards, primarily to assist customers carrying out absorption, distribution, metabolism and excretion (ADME) studies at the pre-clinical or clinical trials stage.

Neal Wesley, technical director at SCM Pharma, said, “As the business has developed and grown over the past few years, we have always tried to adapt to our clients’ changing and increasing potent product manufacturing requirements. We have therefore invested heavily into modifying the facility to ensure we can efficiently deal with a range of different potent projects including small pilot scale, clinical trial progression and the market supply of niche licensed products.”